SE0200356D0 - Novel use - Google Patents
Novel useInfo
- Publication number
- SE0200356D0 SE0200356D0 SE0200356A SE0200356A SE0200356D0 SE 0200356 D0 SE0200356 D0 SE 0200356D0 SE 0200356 A SE0200356 A SE 0200356A SE 0200356 A SE0200356 A SE 0200356A SE 0200356 D0 SE0200356 D0 SE 0200356D0
- Authority
- SE
- Sweden
- Prior art keywords
- sub
- novel use
- quinazolinfyl
- pgd
- quinolin
- Prior art date
Links
- ZJFUTRABUHJURA-UHFFFAOYSA-N 2-(1-quinolin-4-ylindol-3-yl)acetic acid Chemical class C12=CC=CC=C2C(CC(=O)O)=CN1C1=CC=NC2=CC=CC=C12 ZJFUTRABUHJURA-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200356A SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Novel use |
| US10/503,708 US20050165033A1 (en) | 2002-02-05 | 2003-02-04 | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| JP2003565470A JP2005521675A (ja) | 2002-02-05 | 2003-02-04 | 喘息、ｃｏｐｄおよび他の疾患の治療におけるインドール−３−酢酸の使用 |
| EP03703600A EP1474136A1 (en) | 2002-02-05 | 2003-02-04 | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| PCT/SE2003/000184 WO2003066046A1 (en) | 2002-02-05 | 2003-02-04 | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| AU2003206310A AU2003206310A1 (en) | 2002-02-05 | 2003-02-04 | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200356A SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0200356D0 true SE0200356D0 (sv) | 2002-02-05 |
Family
ID=20286889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0200356A SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Novel use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050165033A1 (sv) |
| EP (1) | EP1474136A1 (sv) |
| JP (1) | JP2005521675A (sv) |
| AU (1) | AU2003206310A1 (sv) |
| SE (1) | SE0200356D0 (sv) |
| WO (1) | WO2003066046A1 (sv) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005508164A (ja) * | 2001-10-10 | 2005-03-31 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ２１１３２、ヒトｇタンパク質共役レセプターファミリーメンバーおよびそれらの使用 |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| US7205329B2 (en) | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB2407318A (en) * | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7714132B2 (en) | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| JP2008500991A (ja) | 2004-05-29 | 2008-01-17 | ７ティーエム ファーマ エイ／エス | 医学的使用のためのｃｒｔｈ２レセプターリガンド |
| MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
| JP2008513512A (ja) | 2004-09-21 | 2008-05-01 | アサーシス， インク． | Ｃｒｔｈ２受容体拮抗作用を示すインドール酢酸およびこれらの使用 |
| WO2006068162A1 (ja) * | 2004-12-24 | 2006-06-29 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の治療剤 |
| ES2369782T3 (es) | 2004-12-27 | 2011-12-05 | Actelion Pharmaceuticals Ltd. | Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2. |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| KR101333861B1 (ko) * | 2005-05-24 | 2013-11-28 | 메르크 세로노 에스. 에이. | Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 |
| EP1932839A4 (en) | 2005-09-06 | 2014-09-10 | Shionogi & Co | INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR |
| DK1928457T3 (da) * | 2005-09-30 | 2013-02-04 | Pulmagen Therapeutics Asthma Ltd | Quinoliner og deres terapeutiske anvendelse |
| GB0519969D0 (en) * | 2005-09-30 | 2005-11-09 | Argenta Discovery Ltd | Quinoline compounds |
| GB0524428D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| GB0525141D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525143D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| JP2009538289A (ja) | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
| HUE030850T2 (en) | 2006-06-16 | 2017-06-28 | Univ Pennsylvania | Prostaglandin D2 receptor antagonists for the treatment of hair loss |
| WO2008012511A1 (en) | 2006-07-22 | 2008-01-31 | Oxagen Limited | Compounds having crth2 antagonist activity |
| MY147588A (en) | 2006-08-07 | 2012-12-31 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| NZ585888A (en) | 2007-12-14 | 2012-02-24 | Pulmagen Therapeutics Asthma Ltd | Indoles and their therapeutic use |
| WO2009085177A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
| RS53142B (sr) | 2008-01-18 | 2014-06-30 | Atopix Therapeutics Limited | Jedinjenja koja imaju antagonističku aktivnost na crth2 |
| US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
| US8168673B2 (en) | 2008-01-22 | 2012-05-01 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| US9180114B2 (en) * | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| WO2011055270A1 (en) | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| US8674115B2 (en) | 2009-12-23 | 2014-03-18 | Ironwood Pharmaceuticals, Inc. | CRTH2 modulators |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| CA2790139C (en) | 2010-03-22 | 2018-03-13 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| NZ609955A (en) | 2010-11-09 | 2015-05-29 | Ironwood Pharmaceuticals Inc | Sgc stimulators |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| KR20140113667A (ko) | 2011-12-16 | 2014-09-24 | 아토픽스 테라퓨릭스 리미티드 | 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합 |
| CN104066731B (zh) | 2011-12-27 | 2016-06-15 | 铁木医药有限公司 | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 |
| CN104602763B (zh) | 2012-03-21 | 2018-08-21 | 宾夕法尼亚大学理事会 | 用于调节毛发生长的组合物和方法 |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| SI2970243T1 (sl) | 2013-03-15 | 2020-04-30 | Cyclerion Therapeutics, Inc. | SGC stimulatorji |
| EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| CA2939892C (en) | 2014-03-17 | 2020-03-31 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| CN106103437A (zh) | 2014-03-18 | 2016-11-09 | 埃科特莱茵药品有限公司 | 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途 |
| CA2959757A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
| CA2961489A1 (en) | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| WO2016128565A1 (en) | 2015-02-13 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| WO2017019858A1 (en) | 2015-07-30 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
| CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
| BR112019000293A2 (pt) | 2016-07-07 | 2019-04-16 | Ironwood Pharmaceuticals, Inc. | formas sólidas de um estimulador de sgc |
| KR102513343B1 (ko) | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| US20190183812A1 (en) * | 2017-12-14 | 2019-06-20 | Nmd Pharma A/S | Compounds For The Treatment Of Neuromuscular Disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) * | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| GB1407658A (en) * | 1973-03-06 | 1975-09-24 | Ici Ltd | Process for the manufacture of indole derivatives |
| GB1460348A (en) * | 1974-02-04 | 1977-01-06 | Ici Ltd | Quinazoline derivativesa |
| EP0499143B1 (en) * | 1991-02-09 | 1999-05-06 | B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. | Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation |
| AU3162695A (en) * | 1994-08-03 | 1996-03-04 | Asta Medica Aktiengesellschaft | Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects |
| JP2000297037A (ja) * | 1999-04-15 | 2000-10-24 | Yosuke Tanabe | 乾癬治療剤 |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
-
2002
- 2002-02-05 SE SE0200356A patent/SE0200356D0/sv unknown
-
2003
- 2003-02-04 WO PCT/SE2003/000184 patent/WO2003066046A1/en not_active Ceased
- 2003-02-04 JP JP2003565470A patent/JP2005521675A/ja active Pending
- 2003-02-04 EP EP03703600A patent/EP1474136A1/en not_active Withdrawn
- 2003-02-04 AU AU2003206310A patent/AU2003206310A1/en not_active Abandoned
- 2003-02-04 US US10/503,708 patent/US20050165033A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005521675A (ja) | 2005-07-21 |
| AU2003206310A1 (en) | 2003-09-02 |
| US20050165033A1 (en) | 2005-07-28 |
| EP1474136A1 (en) | 2004-11-10 |
| WO2003066046A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004045618A3 (de) | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| MXPA02011311A (es) | Composicion novedosa. | |
| BG106868A (bg) | Пиримидинови карбоксамиди, приложими като инхибитори на рdе4 изозими | |
| SE0200411D0 (sv) | Novel use | |
| NO20061254L (no) | Farmasoytiske blandinger | |
| DE60334015D1 (de) | Pyridopyrrolizin- und pyridoindolizinderivate | |
| DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
| UA81635C2 (en) | 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12. | |
| ATE402141T1 (de) | Phenäthanolaminderivate zur behandlung von krankheiten der atemwege | |
| DK1718336T3 (da) | Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme | |
| NO20081480L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
| SE9900833D0 (sv) | Novel combination | |
| MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
| SG149876A1 (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| SE9900834D0 (sv) | Novel combination | |
| SG137859A1 (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same | |
| NI200700039A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38. | |
| NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
| MXPA04007294A (es) | Composicion para inhalacion. | |
| DE60203106D1 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| NO20006665D0 (no) | Substituert ß-diketoner og deres anvendelse | |
| WO2003011294A3 (en) | Mucin synthesis inhibitors | |
| WO2005007134A8 (de) | Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum | |
| DK1581224T3 (da) | Tiotropiumholdig lægemiddelsammensætning til inhalation |